Intellia Drops Counterclaims In Gene-Editing Patent Case
Intellia Therapeutics Inc. has agreed to drop a set of claims it asserted in a Delaware federal suit brought by BlueAllele, which accused it of infringing three gene-editing patents to bring...To view the full article, register now.
Already a subscriber? Click here to view full article